Additional Information

Description

Granix (tbo-filgrastim) 480 mcg/0.8 mL is a recombinant human granulocyte colony-stimulating factor (G-CSF) analog. It stimulates neutrophil production in patients with chemotherapy-induced neutropenia, reducing the incidence of infection-related complications. The medication binds to G-CSF receptors on hematopoietic cells, promoting the proliferation, differentiation, and activation of neutrophils.

Granix is administered as a subcutaneous injection, with dosing typically initiated 24 hours after chemotherapy. The recommended dose for adults is 5 mcg/kg per day until an adequate neutrophil count is achieved. The injection should be given in the abdomen, upper arm, or thigh, rotating sites to minimize irritation. The prefilled syringe allows for precise dosing and reduces the risk of contamination.

Adverse effects include bone pain, headache, injection site reactions, and fatigue. Serious risks involve splenic rupture, acute respiratory distress syndrome, and capillary leak syndrome. Regular monitoring of complete blood counts is necessary to assess neutrophil levels and detect any hematologic abnormalities. Patients should be advised to report sudden pain in the left upper abdomen or shoulder, which may indicate splenic rupture.